




Instance: composition-en-8f194b3a85e80bebf07798b496672e52
InstanceOf: CompositionUvEpi
Title: "Composition for hbvaxpro Package Leaflet"
Description:  "Composition for hbvaxpro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/01/183/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8f194b3a85e80bebf07798b496672e52)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hbvaxpro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What HBVAXPRO 5 micrograms is and what it is used for</li>
<li>What you need to know before you or your child receive HBVAXPRO 5 micrograms</li>
<li>How HBVAXPRO 5 micrograms is given</li>
<li>Possible side effects</li>
<li>How to store HBVAXPRO 5 micrograms</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What hbvaxpro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What hbvaxpro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This vaccine is indicated for active immunisation against hepatitis B virus infection caused by all known
subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis B
virus.
It can be expected that hepatitis D will also be prevented by immunisation with HBVAXPRO as hepatitis
D does not occur in the absence of hepatitis B infection.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis
E and other pathogens known to infect the liver. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take hbvaxpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take hbvaxpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use HBVAXPRO 5 micrograms
- if you or your child is allergic to hepatitis B surface antigen or to any of the other ingredients of
HBVAXPRO (see section 6)
- if you or your child has a severe illness with fever
Warnings and precautions
The container of this vaccine contains latex rubber. Latex rubber may cause severe allergic reactions.
Talk to your doctor, pharmacist or nurse before you or your child receives HBVAXPRO 5 micrograms.
Other vaccines and HBVAXPRO 5 micrograms
HBVAXPRO can be administered at the same time as with hepatitis B immunoglobulin, at a separate
injection site.
HBVAXPRO can be used to complete a primary immunisation course or as a booster dose in subjects who
have previously received another hepatitis B vaccine.
HBVAXPRO may be administered at the same time as with some other vaccines, using separate sites and
syringes.
Tell your doctor, pharmacist or nurse if you or your child is taking, or has recently taken, any other
medicines, including medicines obtained without a prescription.
Pregnancy and breast-feeding
Caution should be exercised when prescribing the vaccine to pregnant or breast-feeding women.
Ask your doctor, pharmacist or nurse for advice before taking any medicine.
Driving and using machines 
HBVAXPRO is expected to have no, or negligible, influence on the ability to drive and use machines.
HBVAXPRO 5 micrograms contains sodium: This medicinal product contains less than 1 mmol
sodium (23 mg) per dose, that is to say essentially  sodium- free .</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take hbvaxpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take hbvaxpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dosage
The recommended dose for each injection (0.5 mL) is 5 micrograms for individuals from birth through
15 years of age.
A course of vaccination should include at least three injections.
Two immunisation schedules can be recommended:</p>
<ul>
<li>two injections with an interval of one month followed by a third injection 6 months after the first
administration (0, 1, 6 months).</li>
<li>if immunity is needed quickly: three injections with an interval of one month and a fourth dose 1
year later (0, 1, 2, 12 months).
In case of a recent exposure to the hepatitis B virus, a first dose of HBVAXPRO together with the
appropriate dose of immunoglobulin can be given.
Some local vaccination schedules currently include recommendations for a booster dose. Your doctor,
pharmacist or nurse will inform you if a booster dose should be given.
Method of administration
The vial should be well shaken until a slightly opaque white suspension is obtained.
Once the vial has been penetrated, the withdrawn vaccine should be used promptly, and the vial must be
discarded.
The doctor or nurse will give the vaccine as an injection into muscle. The upper side of the thigh is the
preferred site for injection in neonates and infants. The upper arm muscle is the preferred site for injection
in children and adolescents.
This vaccine should never be given into a blood vessel.
Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopaenia
(diminution of blood platelets) or to persons at risk of haemorrhage.
If you or your child forget one dose of HBVAXPRO 5 micrograms 
If you or your child miss a scheduled injection, talk to your doctor, pharmacist or nurse. Your doctor or
nurse will decide when to give the missed dose.
If you or your child have any further questions on the use of this product, ask your doctor, pharmacist or
nurse.</li>
</ul> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this vaccine can cause side effects, although not everybody gets them.
As with other hepatitis B vaccines, in many instances, the causal relationship of side effects to the vaccine
has not been established.
The most common side effects seen are injection-site reactions: soreness, redness and hardening.
Other side effects are reported very rarely: </p>
<p>Low platelet count, Lymph node disease</p>
<p>Allergic reactions</p>
<p>Nervous system disorders such as pins and needles, Facial paralysis, Nerve inflammations including
Guillain-Barre Syndrome, Inflammation of the nerve of the eye that leads to impaired vision, Brain
inflammation, Exacerbation of multiple sclerosis, Multiple sclerosis, Convulsions, Headache,
Dizziness and Fainting</p>
<p>Low blood pressure, Blood vessel inflammation</p>
<p>Asthma-like symptoms</p>
<p>Vomiting, Nausea, Diarrhoea, Abdominal pain</p>
<p>Skin reactions such as eczema, Rash, Itching, Hives and Skin blistering, Hair loss</p>
<p>Joint pain, Arthritis, Muscle pain, Pain in extremity</p>
<p>Fatigue, Fever, Vague illness, Flu-like symptoms</p>
<p>Elevation of liver enzymes</p>
<p>Inflammation of the eye which causes pain and redness 
In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between
breaths may occur for 2-3 days after vaccination.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system listed in
Appendix V. By reporting side effects you can help provide more information on the safety of this
medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store hbvaxpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store hbvaxpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the label.
Store in a refrigerator (2 C - 8 C). 
Do not freeze.
Store in the original package in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What HBVAXPRO 5 micrograms contains
The active substance is :
Hepatitis B virus surface antigen, recombinant (HBsAg) * ...................<br />
5 micrograms
Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.25 milligram Al+)#
* produced in Saccharomyces cerevisiae (strain 2150-2-3) yeast by recombinant DNA technology.</p>
<h1>Amorphous aluminium hydroxyphosphate sulfate is included in this vaccine as an adsorbant. Adsorbants</h1>
<p>are substances included in certain vaccines to accelerate, improve and/or prolong the protective effects of
the vaccine.
The other ingredients are sodium chloride (NaCl), borax and water for injections.
What HBVAXPRO 5 micrograms looks like and contents of the pack
HBVAXPRO 5 micrograms is a suspension for injection in a vial.
Pack sizes of 1 and 10 vials without syringe/needle.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
For any information about this vaccine, please contact the local representative of the Marketing
Authorisation Holder.
Belgi /Belgique/Belgien
MSD Belgium<br />
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.msd_lietuva@merck.com</p>
<pre><code>       ,
</code></pre>
<p>.: + 359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium<br />
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o. 
Tel.: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com 
Eesti
Merck Sharp &amp; Dohme O , 
Tel: +372.614.4msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.msdpolska@merck.com
France
MSD France
T l: +33 (0)1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Tel: +386.1.520.4msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi </p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 :  800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last approved in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu. 
The following information is intended for medical or health care professionals only:
Instructions
The vaccine should be inspected visually prior to administration for any foreign particulate matter and/or
abnormal physical appearance. The vial should be well shaken until a slightly opaque white suspension is
obtained.
Package leaflet: Information for the user
HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe
Hepatitis B vaccine (recombinant DNA)
Read all of this leaflet carefully before you or your child is vaccinated because it contains important
information.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.</p> </div>"""      



Instance: composition-da-8f194b3a85e80bebf07798b496672e52
InstanceOf: CompositionUvEpi
Title: "Composition for hbvaxpro Package Leaflet"
Description:  "Composition for hbvaxpro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/01/183/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8f194b3a85e80bebf07798b496672e52)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hbvaxpro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du eller dit barn får HBVAXPRO 5 mikrogram
3. Sådan får du eller dit barn HBVAXPRO 5 mikrogram
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine er indiceret til aktiv immunisering (vaccination) mod hepatitis B-virusinfektion
forårsaget af alle kendte subtyper til børn fra fødslen til og med 15 år, som anses for at have en risiko
for at blive udsat for hepatitis B-virus.
Det forventes, at vaccination med HBVAXPRO også vil beskytte mod hepatitis D, idet hepatitis D
ikke optræder, medmindre hepatitis B infektion også er til stede.
Vaccinen beskytter ikke mod infektion forårsaget af hepatitis A, hepatitis C og hepatitis E eller andre
patogener, der inficerer leveren.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  hbvaxpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  hbvaxpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du/dit barn må ikke få HBVAXPRO 5 mikrogram
- hvis du eller dit barn er allergisk over for hepatitis B overflade-antigen eller et af de øvrige
indholdsstoffer i HBVAXPRO (angivet i punkt 6)
- hvis du eller dit barn har en alvorlig sygdom med feber
Advarsler og forsigtighedsregler 
Beholderen til denne vaccine indeholder latexgummi. Latexgummi kan forårsage alvorlige allergiske
reaktioner.
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du eller dit barn får HBVAXPRO
5 mikrogram.
Brug af andre vacciner og HBVAXPRO 5 mikrogram
HBVAXPRO kan administreres samtidigt med hepatitis B immunglobulin, men på 2 forskellige
injektionssteder.
HBVAXPRO kan anvendes til at fuldføre en primær immunisering eller som revaccination hos
personer, der tidligere har fået en anden hepatitis B-vaccine.</p>
<p>60
HBVAXPRO kan administreres samtidigt med visse andre vacciner, idet der dog skal anvendes
separate sprøjter, og vaccinerne skal gives på forskellige injektionssteder.
Fortæl det altid til lægen, apotekspersonalet eller sygeplejersken, hvis du eller dit barn bruger
anden medicin, for nylig har brugt anden medicin eller planlægger at bruge anden medicin.
Dette gælder også medicin, som ikke er købt på recept.
Graviditet og amning
Der skal udvises forsigtighed ved ordination af vaccinen til gravide eller ammende kvinder.
Spørg din læge, apotekspersonalet eller sygeplejersken til råds, før du eller dit barn tager nogen form
for medicin.
Trafik- og arbejdssikkerhed
Det forventes, at HBVAXPRO har ingen eller kun ubetydelig indflydelse på evnen til at føre
motorkøretøj og betjene maskiner. 
HBVAXPRO 5 mikrogram indeholder natrium 
Denne vaccine indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, det vil sige, den er i det
væsentlige "natriumfri". </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage hbvaxpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage hbvaxpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dosering
Den anbefalede dosis pr. injektion (0,5 ml) er 5 mikrogram til børn fra fødslen til og med 15 år.
Et vaccinationsprogram bør indeholde mindst 3 injektioner.
To vaccinationsprogrammer kan anbefales:</p>
<ul>
<li>2 injektioner med 1 måneds interval efterfulgt af en tredje injektion 6 måneder efter første
administration (0, 1, 6 måneder).</li>
<li>hvis hurtig beskyttelse ønskes: 3 injektioner med 1 måneds interval efterfulgt af en 4. dosis 1 år
senere,  (0, 1, 2, 12 måneder).
I tilfælde af eksponering for hepatitis B-virus for nylig, kan den første dosis HBVAXPRO
5 mikrogram administreres samtidigt med en hensigtsmæssig dosis immunglobulin.
For tiden omfatter nogle lokale vaccinationsprogrammer en anbefaling om en boosterdosis. Din læge,
apotekspersonalet eller sygeplejersken vil informere om, hvorvidt en boosterdosis skal gives.
Administration
Hætteglasset skal omrystes grundigt, indtil der forekommer en svagt opaliserende, hvid suspension. 
Når hætteglassets forsegling er blevet brudt, skal den udtrukne vaccine anvendes med det samme, og
hætteglasset smides ud.
Lægen eller sygeplejersken giver vaccinen som en intramuskulær injektion. Den øverste del af låret er
det anbefalede injektionssted hos nyfødte og spædbørn. Overarmsmusklen er det anbefalede
injektionssted hos børn og unge.
Denne vaccine må aldrig injiceres i et blodkar.
Undtagelsesvist kan vaccinen injiceres subkutant hos patienter med trombocytopeni (nedsat antal
blodplader) eller risiko for blødning.</li>
</ul>
<p>61
Hvis du eller dit barn har glemt en dosis HBVAXPRO 5 mikrogram 
Tal med lægen, apotekspersonalet eller sygeplejersken, hvis du eller dit barn mangler at få en planlagt
injektion. Lægen eller sygeplejersken bestemmer, hvornår den manglende dosis skal gives.
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du eller dit barn er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Som med andre hepatitis B-vacciner er en årsagssammenhæng mellem vaccinen og bivirkninger i
mange tilfælde ikke påvist.
De bivirkninger, som hyppigst ses, er reaktioner på injektionsstedet: ømhed, rødme og hårdhed. 
Andre bivirkninger, som indberettes meget sjældent:</p>
<ul>
<li>lavt antal blodplader, sygdom i lymfekirtlerne</li>
<li>allergiske reaktioner</li>
<li>sygdomme i nervesystemet såsom prikken i huden, ansigtslammelse, nervebetændelse inklusive </li>
<li>Guillain-Barrés syndrom, betændelse i synsnerven, som fører til nedsat syn, hjernebetændelse,
forværring af multipel sklerose, multipel sklerose, kramper, hovedpine, svimmelhed og
besvimelse</li>
<li>lavt blodtryk, betændelse i blodkar</li>
<li>astmalignende symptomer</li>
<li>opkastning, kvalme, diarré, mavesmerter</li>
<li>hudreaktioner såsom eksem, udslæt, kløe, nældefeber og blæredannelse, hårtab</li>
<li>ledsmerter, ledbetændelse, muskelsmerter, smerter i arme eller ben</li>
<li>træthed, feber, utilpashed, influenzalignende symptomer</li>
<li>forhøjede leverenzymværdier</li>
<li>betændelse i øjet, som kan give smerter og rødme.
Hos meget præmature spædbørn (født i eller før 28. svangerskabsuge) kan der ses respirationspauser,
der er længere end normalt, i 2 til 3 dage efter vaccination.
Indberetning af bivirkninger
Hvis du eller dit barn oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller
sygeplejersken. Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel.
Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger, kan du eller
dit barn hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.</li>
</ul> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn.
Brug ikke vaccinen efter den udløbsdato, der står på pakningen.
Opbevares i køleskab (2 °C - 8 °C).
Må ikke nedfryses.
Opbevares i den originale yderpakning for at beskytte mod lys.
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>
<p>62</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HBVAXPRO 5 mikrogram indeholder:
Aktivt stof:
Hepatitis B virus overflade-antigen, rekombinant (HBsAg) * ............... 5  mikrogram
Adsorberet til amorf aluminiumhydroxidphosphatsulfat (0,25 milligram Al+)#</p>
<ul>
<li>Fremstillet i Saccharomyces cerevisiae (stamme 2150-2-3) gærceller med rekombinant DNA-
teknologi.</li>
</ul>
<h1>Amorf aluminiumhydroxyphosphatsulfat er tilsat denne vaccine som et adsorberende stof.</h1>
<p>Adsorberende stoffer er substanser, som tilsættes visse vacciner for at fremskynde, forbedre og/eller
forlænge vaccinens beskyttende virkninger.
Øvrige indholdsstoffer: natriumchlorid (NaCl), natriumborat og vand til injektionsvæsker.
Udseende og pakningsstørrelser
HBVAXPRO 5 mikrogram er en suspension til injektion i et hætteglas.
Pakningsstørrelser på 1 og 10 hætteglas uden sprøjte/nål.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Holland
Hvis du ønsker yderligere oplysninger om denne vaccine, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien 
MSD Belgium <br />
Tél/Tel: 32(0)27766dpoc_belux@merck.com 
Lietuva
UAB Merck Sharp &amp; Dohme
Tel.: +370.5.2780.247
msd_lietuva@merck.com
България 
Мерк Шарп и Доум България ЕООД,<br />
тел.: + 359 2 819 3info-msdbg@merck.com 
Luxembourg/Luxemburg
MSD Belgium<br />
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika 
Merck Sharp &amp; Dohme s.r.o.<br />
Tel.: +420 233 010 dpoc_czechslovak@merck.com 
Magyarország
MSD Pharma Hungary Kft.
Tel.: + 36.1.888.5300
hungary_msd@merck.com
Danmark 
MSD Danmark ApS 
Tlf: + 45 4482 4dkmail@merck.com 
Malta
Merck Sharp &amp; Dohme Cyprus Limited.
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland 
MSD Sharp &amp; Dohme GmbH 
Tel: 0800 673 673 673 (+49 (0) 89 4561 0) 
e-mail@msd.de 
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999000 (+31 23 5153153)
medicalinfo.nl@merck.com </p>
<p>63
Eesti
Merck Sharp &amp; Dohme OÜ, 
Tel: +372.614.4200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel.: +48.22.549.51.00
msdpolska@merck.com
France
MSD France
Tél: +33 (0)1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: +385 1 66 11 333
croatia_info@merck.com
România
Merck Sharp &amp; Dohme Romania S.R.L
Tel: + 4021 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o.
Tel: +386.1.520.4201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r.* Tel: +421 2 58282010
dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi 
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ:  800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: +371.67364.224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om HBVAXPRO på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</p>
<p>64
Nedenstående oplysninger er til læger og sundhedspersonale:
Instruktioner
Vaccinen skal inspiceres visuelt for tilstedeværelse af partikler og misfarvning forud for
administration. Hætteglasset skal omrystes omhyggeligt, indtil en svagt uigennemsigtig, hvid
suspension er opnået. </p>
<p>65
Indlægsseddel: Information til brugeren
HBVAXPRO 5 mikrogram, injektionsvæske, suspension i fyldt injektionssprøjte
Hepatitis B-vaccine (rekombinant DNA)
Læs denne indlægsseddel grundigt, inden du eller dit barn bliver vaccineret, da den indeholder
vigtige oplysninger.
- 
Gem indlægssedlen. Du kan få brug for at læse den igen.
- 
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er mere, du vil vide.
- Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis du eller dit barn får bivirkninger,
herunder bivirkninger, som ikke er nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk.</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-8f194b3a85e80bebf07798b496672e52
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hbvaxpro Package Leaflet for language en"
Description: "ePI document Bundle for hbvaxpro Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8f194b3a85e80bebf07798b496672e52"
* entry[0].resource = composition-en-8f194b3a85e80bebf07798b496672e52

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8f194b3a85e80bebf07798b496672e52"
* entry[=].resource = mp8f194b3a85e80bebf07798b496672e52
                            
                    
Instance: bundlepackageleaflet-da-8f194b3a85e80bebf07798b496672e52
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hbvaxpro Package Leaflet for language da"
Description: "ePI document Bundle for hbvaxpro Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8f194b3a85e80bebf07798b496672e52"
* entry[0].resource = composition-da-8f194b3a85e80bebf07798b496672e52

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8f194b3a85e80bebf07798b496672e52"
* entry[=].resource = mp8f194b3a85e80bebf07798b496672e52
                            
                    



Instance: mp8f194b3a85e80bebf07798b496672e52
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product HBVAXPRO 5 micrograms, suspension for injection"
Description: "HBVAXPRO 5 micrograms, suspension for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/01/183/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "HBVAXPRO 5 micrograms, suspension for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8f194b3a85e80bebf07798b496672e52ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "hbvaxpro"

* status = #current
* mode = #working

* title = "List of all ePIs associated with hbvaxpro"

* subject = Reference(mp8f194b3a85e80bebf07798b496672e52)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#hbvaxpro "hbvaxpro"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8f194b3a85e80bebf07798b496672e52) // hbvaxpro en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8f194b3a85e80bebf07798b496672e52) // hbvaxpro da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8f194b3a85e80bebf07798b496672e52
InstanceOf: List

* insert 8f194b3a85e80bebf07798b496672e52ListRuleset
    